Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan

详细信息    查看全文

• 作者：Takashige Abe ; M.D. ; Ph.d^a ; ^{takataka@rf6.so-net.ne.jp} ; Junji Ishizaki ; M.D.^b ; Hiroshi Kikuchi ; M.D.^a ; Keita Minami ; M.D. ; Ph.d^b ; Ryuji Matsumoto ; M.D. ; Ph.d^a ; Toru Harabayashi ; M.D. ; Ph.d^b ; Ataru Sazawa ; M.D. ; Ph.d^b ; Tango Mochizuki ; M.D.^b ; Satoshi Chiba ; M.D.^b ; Tomoshige Akino ; M.D. ; Ph.d^b ; Masashi Murakumo ; M.D. ; Ph.d^b ; Naoto Miyajima ; M.D. ; Ph.d^a ; Kunihiko Tsuchiya ; M.D. ; Ph.d^a ; Satoru Maruyama ; M.D. ; Ph.d^a ; Sachiyo Murai ; M.D.^a ; Nobuo Shinohara ; M.D. ; Ph.d^a
• 关键词：Metastatic urothelial carcinoma ; Systemic chemotherapy ; Metastasectomy
• 刊名：Urologic Oncology: Seminars and Original Investigations
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：35
• 期：2
• 页码：38.e1-38.e8
• 全文大小：273 K
• 卷排序：35

文摘

To clarify prognostic factors of metatstatic UC in the Japanese population. The median overall survival time was 17 months. Female, good PS, Hb≥10 g/dl, and single organ metastasis were favorable pretreatment factors. Metastasectomy was associated with long-term disease control.